Osteopenia/osteoporosis (O/O) has been associated with allogeneic stem cell transplantation (alloSCT). We retrospectively reviewed 102 patients undergoing a first alloSCT from 2000 to 2005 at our center to evaluate the prevalence of O/O p6 and 46 months post-alloSCT. Fifty-six patients did not have a dual energy X-ray absorptiometry (DXA) scan following alloSCT. Approximately half (n ¼ 13/27) of those with a first DXA scan p6 months post-alloSCT had O/O and a similar rate (n ¼ 9/19) was seen in those with a first DXA scan 46 months. There were no significant differences in patient characteristics between the normal and O/O groups. The dual femur (DF) appeared to be more vulnerable to alloSCTinduced bone mineral density (BMD) loss than the lumbar spine (LS), regardless of screening time. O/O patients were treated with bisphosphonates and 41% had a repeat DXA scan post-treatment. No patient developed jaw osteonecrosis and significant BMD improvement was seen at the LS (mean BMD, 1.03 ± 0.13 vs 1.08 ± 0.12, P ¼ 0.004) but not the DF (mean BMD, 0.84±0.06 vs 0.85 ± 0.08, P ¼ 0.29), indicating BMD loss at the DF is more resistant than the LS to antiresorptive therapy. Our results demonstrate that O/O is an early and late complication post-alloSCT and bisphosphonate treatment reverses BMD loss at the LS.
Introduction
Osteopenia/osteoporosis (O/O) refers to pathologic bone mineral density (BMD) loss which cumulatively makes bone thin and fragile, resulting in the increased risk of osteoporotic fracture. 1 Generally, there is an exponential relationship between decline in BMD and increased fracture risk, where a 10-15% decrease in BMD approximately doubles the risk of fracture. 2 Fractures have a significant impact on quality-oflife and health care costs and can sometimes lead to premature death. 3 Dual energy X-ray absorptiometry (DXA) scan, which measures the bone density by X-ray absorption is the most widely used test for reasons of accuracy, convenience, noninvasiveness and low cost. 4 The incidence of O/O and subsequent risk of osteoporotic fracture rises most significantly in the elderly, especially in postmenopausal women. 5 O/O is also a common complication after solid organ transplantation. 6 It has been described after hematopoietic stem cell transplantation (SCT) as well, with the majority of cases reported in alloSCT recipients. [7] [8] [9] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] AlloSCT-associated BMD loss is usually described in the first 6-12 months after the transplantation, but varies widely from 40 days 17 to 4-6 years after the transplantation, 30, 31, 34 and in some instances can persist for 10-12 years. 26, 28 Baseline BMD pre-SCT is usually within the normal limits; [15] [16] [17] 24, [27] [28] [29] [30] 33 the few exceptions noting high O/O prevalence pre-SCT are probably due to the underlying diseases or intensive chemotherapy prior to the transplantation. 12, 14, 20, 32 The femoral neck (FN) and lumbar spine (LS) are two of the most frequently measured sites for BMD assessment and studies have shown differential effects in the extent and length of post-alloSCT BMD loss between these two sites. It has been reported that the bone loss was more pronounced at the FN compared to the LS. 21, 30 While spinal BMD recovered during further follow-up, BMD continuously declined at the femur. The underlying mechanism responsible for the differences is not clear.
In this study, we sought to describe and characterize the prevalence of O/O in a contemporary cohort of patients who had their first DXA scan early (p6 months) vs late (46 months) following their first alloSCT. In a novel approach, response to antiresorptive bisphosphonate treatment was evaluated among patients who had a follow-up DXA scan.
Patients and methods

Study population and design
One hundred and two consecutive patients who were 18 years of age or older and underwent a first alloSCT at Roswell Park Cancer Institute (RPCI) between 1 January 2000 and 3 January 2005 were retrospectively reviewed for DXA scans and outcomes. Eighty-five patients survived to day þ 100. During the study period, DXA scans were not routinely performed for all alloSCT patients but done at the physician's discretion. Forty-six patients who had DXA scans were stratified into early screening (performed p6 months post-SCT, n ¼ 27) and late screening (performed 46 months post-SCT, n ¼ 19) groups. Institutional Review Board (IRB) approval from RPCI was obtained to conduct this existing data review and all summarized data have been de-identified.
Patient follow-up All 22 patients diagnosed with O/O received antiresorptive bisphosphonate therapy. A follow-up DXA scan was conducted in nine patients to evaluate treatment response. Patients who developed Glucksberg Grade II to IV acute graft-versus-host-disease (aGVHD) 36, 37 were treated with methylprednisolone (2 mg/kg/day); six patients with aGVHD had a normal initial DXA scan and subsequently had a follow-up scan.
Bone mineral density assessment
The GE s Lunar Prodigyt was used to quantify bone density; all patients were scanned using the same machine at the same center. The coefficient of variance (CV), which measures the precision error of the scanner, is 0.95% at the anterior/posterior spine. Therefore, the least significant change in BMD at the spine between two scans must exceed 2.77 Â 0.95% or 2.62% in order to state with 95% confidence that the change in BMD was not due to random variability. 38 BMD was measured at the LS (average measure at L2, L3 and L4) and the DF (average of two entire femora). The T score measures the BMD s.d. below that of the healthy young adults whereas the Z score measures the BMD standard deviations below age-and sex-matched healthy controls. Both T and Z score results are reported. Patients were classified into osteopenia, osteoporosis or normal groups according to WHO criteria: a T score pÀ2.5 is defined as osteoporosis; a T score pÀ1.0 and 4À2.5 is osteopenia; and a T score 4À1.0 indicates normal bone density. 1 We categorized osteopenia and osteoporosis into a single O/O group in our analysis due to limited sample size. Given the broad range of age, Z scores were provided and compared with T score as an evaluation of any overestimation of age-associated BMD loss. Patients less than 18 years of age were not included in this study because of the lack of standard T and Z scoring for pediatric patients.
Statistical analysis
Univariate analysis used two sample t-tests, w 2 -test or Fisher's exact test, wherever appropriate. Repeated measures analysis of variance (ANOVA) and the Wilcoxon signed-rank rest were used for comparisons between baseline and follow-up BMD. Survival analysis curves were calculated according to the Kaplan-Meier method 39 and compared using the log-rank test. All statistical analyses were performed using SAS 9.1 (SAS Institute, Cary, NC, USA).
Results
Patient characteristics
Patient characteristics are summarized in Table 1 . There were no significant differences between those who had a DXA scan (n ¼ 46) and those who did not (n ¼ 56). Table 2 shows characteristics of patients in the O/O and normal groups by early vs late screening. The only statistically significant difference was the underlying disease between the normal and O/O groups in the late screening period (P ¼ 0.05). Since glucocorticoid use has been associated with transplantation-related BMD loss, we compared the differences in the rates of grade II-IV aGVHD and in the usage of glucocorticoid-containing GVHD prophylaxis between the O/O and normal groups ( Table 2 ). More than half (n ¼ 54/102) of all patients did not receive glucocorticoids. Among patients who had DXA scans, 10/22 O/O patients and 9/24 normal patients received glucocorticoids (P ¼ 0.55). We repeated the analyses stratified by early vs late screening time and no significant differences in glucocorticoid exposure were found between the normal and O/O groups (data not shown). Kaplan-Meier survival analysis demonstrated improved survival among patients who did vs who did not have a DXA scan (Po0.0001). This reflects the more stable clinical status of patients who can undergo a DXA scan. However, there was no significant difference in overall survival between the normal and O/O groups who had a DXA scan either within 6 months (P ¼ 0.21) or after 6 months (P ¼ 0.29) post-alloSCT.
Since menopause has a known association with O/O, we assessed the menopausal status of the women in this study. According to the National Comprehensive Cancer Network (NCCN) guidelines, an acceptable indicator of menopause in breast cancer studies is age X60 years. 40 Amenorrhea is not a reliable indicator of menopause in women who have received chemotherapy, since it may cause a temporary cessation of menses without a lowering of estradiol levels. In this retrospective study, all patients had received pre-BMT chemotherapy and hormone levels were not drawn for most women in this study. Therefore, we used age at the time of BMT as a surrogate measure of menopausal status. The median (range) age at the time of BMT/DXA scan in all female patients was 41.5 years. In women who had O/O, the median (range) age was 38 (25-66) years. Using age X60 years to define menopause, 96% of female subjects in this study population were pre-menopausal at the time of BMT and DXA scan. As a sensitivity analysis using age X55 years to define menopause, 91% of the female subjects in this study were premenopausal. Since women comprised less than half of this study population and 490% were pre-menopausal, it is unlikely that menopausal status has overestimated the rate of O/O in this study.
BMD loss after alloSCT
Among patients in the early screening group, approximately half (n ¼ 13/27) showed evidence of pathologic BMD loss at either the LS or the DF at a median screening time of 108 days (range 35-160 days) post-SCT. The rate of O/O at the DF and LS was 11/27 and 10/27, respectively ( (Table 3) . We did not detect a difference in the rate of O/O or BMD measurements at either the LS or the DF between the early (p6 months) and late (46 months) screening groups (Table 3) .
Follow-up DXA scans Six patients with normal BMD and nine patients with O/O at their first DXA scan post-SCT had a repeat BMD measurement at a median screening time of 356 days (range 146-723 days) after their first measurement. Among patients with normal BMD at the first scan, BMD remained within the normal range but decreased at the LS (À4%, P ¼ 0.43) and the DF (À8%, P ¼ 0.16) on the follow-up DXA scan. Those who had O/O at the time of first DXA scan received antiresorptive bisphosphonate therapy. The mean BMD significantly increased by 5% at the LS (P ¼ 0.004) (larger than the 95% least significant change of 2.62%), but did not change at the DF (1%, P ¼ 0.29). No patients developed osteonecrosis of the jaw after receiving bisphosphonate treatment.
Discussion
We report a high prevalence of O/O following alloSCT in a retrospective single center study. O/O occurs at similar rates in both the early and late screening groups postalloSCT, and the DF appears to be more vulnerable to BMD loss than the LS. Our finding of early-onset O/O after alloSCT suggests close and early (by day þ 100) monitoring of BMD changes following alloSCT. Antiresorptive bisphosphonate therapy effectively reversed BMD loss at the LS but not at the DF in our patients, which is consistent with previous findings. 41 In addition, we did not observe any cases of osteonecrosis of the jaw in our patients after the bisphosphonate treatment, which has been described previously. [42] [43] [44] This may be due to the relatively small number of bisphosphonate-treated patients in our study or to other factors such as the association of extended intravenous bisphosphonate therapy with osteonecrosis.
Limitations of this study are related to the small sample size and its retrospective nature, namely the inconsistent application of DXA scans post-SCT, the lack of baseline pre-SCT DXA scans for comparison and 'survivor bias' whereby the patient survived and was medically stable for DXA scan testing. Nevertheless, our estimation of O/O prevalence was in concordance with the previous reports. A cross-sectional study by Buchs et al. 21 reported an O/O prevalence of 35% at about 1-week post-alloSCT and 50% at a median time of 5-year (0.5-13 years) post-alloSCT, without a baseline BMD for comparison. Another study reported the incidence of O/O in alloSCT patients at discharge from initial SCT was 38 and 45% at 6 months, which are comparable with our estimation of 48% O/O within 6 months post-SCT. 30 In the same study, baseline DXA scans demonstrated a pre-SCT O/O incidence of 31%. Acute GVHD grade II-IV and glucocorticoid-containing GvHD prophylaxis are combined as an indicator of glucocorticoid exposure: none, not exposed to glucocorticoid from either source; either, exposed to corticosteriod from one of the two sources; both, exposed to glucocorticoid from both sources.
Immunosuppressive regimens consisting of glucocorticoids and the calcineurin inhibitors, cyclosporine and tacrolimus, after alloSCT are similar to those used after solid organ transplantation. Prior research has shown that glucocorticoids most strongly, and calcineurin inhibitors to a lesser extent, correlated with accelerated BMD loss after solid organ transplantation, 45, 46 which was repeatedly observed in alloSCT patients. 12, 22, 30 In addition, glucocorticoids are administered as part of induction and salvage regimens for patients with ALL, myeloma and lymphoma before SCT, 47 which may predispose them to a high risk of bone loss pre-and post-SCT. However, in our study, we did not find this association, which is consistent with the findings from two other studies.
11, 13 The relatively low proportion of patients receiving glucocorticoids may explain the absence of an association between O/O and Acute GvHD grade II-IV treatment and glucocorticoid-containing GvHD prophylaxis regimens were combined as an indicator of glucocorticoid exposure: none ¼ not exposed to glucocorticoid from either source; either ¼ exposed to glucocorticoids from either GVHD treatment or prophylaxis; both ¼ exposed to glucocorticoids during both prophylaxis and treatment of GVHD.
O/O post-allogeneic SCT S Yao et al glucocorticoid use in our study. Nevertheless, an important implication of the high prevalence of O/O and low usage of glucocorticoids in our study is that factors in addition to glucocorticoids may be responsible for BMD loss postalloSCT. This is further supported by the common observation of decreased BMD post-autologous SCT in the absence of glucocorticoid exposure. 22, 27 Mechanisms other than glucocorticoid use have been postulated to cause BMD loss post-SCT, including hypogonadism, secondary hyperparathyroidism due to decreased serum levels of calcium and vitamin D and direct toxicity to bone cells and bone marrow stromal cells. Since BMD loss post-SCT can occur early post-BMD, we hypothesize that the rapid changes in cytokines immediately following SCT may also play an important role in promoting rapid BMD loss. Alternatively, patients may have BMD loss prior to SCT, which is exacerbated by the SCT process. Currently, vitamin D and calcium supplementation are the mainstays of O/O prevention post-SCT along with the introduction of bisphosphonates. Strategies for further decreasing this complication may include the use of newer agents such as RANKL inhibitor, post-SCT physical therapy and earlier post-BMT DXA screening and hormonal replacement. 
